San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.

Following a setback with the company’s experimental major depressive disorder medicine in December, SAGE Therapeutics will initiate a corporate restructuring that includes halving the drug manufacturer’s employee headcount in order to focus resources on the development of the product pipeline.

Cambridge, Massachusetts-based Unum Therapeutics announced a restructuring in order to shift assets toward the company’s preclinical program, BOXR1030, for solid tumors.

As Sanofi continues to undergo a planned renovation announced in December 2019, the company will do so without four long-time executives.

Teva Pharmaceutical Industries said a two-year restructuring enabled the world’s largest generic drugmaker to turn a corner, as the company reported slightly better than expected fourth-quarter 2019 results.

With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.

Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.

Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.

For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

Acorda Therapeutics will terminate approximately 25 percent of headcount as the company initiates a corporate restructuring.